echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Antitumor Therapy > Gilead has committed $800 million to Jounce to create innovative cancer immunotherapy.

    Gilead has committed $800 million to Jounce to create innovative cancer immunotherapy.

    • Last Update: 2020-09-23
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    Gilead Sciences announced a meeting with Jounce Therapeutics (JNCE. US) has reached a partnership agreement under which Gilead will obtain exclusive research and development licenses for Jounce's JTX-1811 project, pay Jounce an $85 million advance and make a $35 million equity investment.
    , Jounce is expected to receive follow-up payments of up to $685 million in the future based on clinical, regulatory and commercial milestones.
    it is understood that Jounce was founded in 2013 and co-founded by James P. Allison, professor of immunology and dean of the department at the Anderson Cancer Center at the University of Texas, usa, who jointly won the 2018 Nobel Prize in Physiology or Medicine on October 1, 2018.
    Jounce's commitment to immunotherapy is characterized not by direct treatment of patient tumors, but by managing the patient's immune system to enable it to independently detect and attack cancer cells and malignancies.
    2013, Jounce received $47 million in round A financing and $56 million in round B financing in 2015.
    the key projects currently being developed by Jounce include monoclonal antibody JTX-2011, which stimulates induced costulent molecules, and super-T cells that disrupt target interactions on tumor-related macrophages.
    JTX-1811 in this protocol is a monoclonal antibody designed to selectively remove immunosuppressive tumor-immersive regulatory T (TITR) cells.
    target of JTX-1811 is CCR8, a chemical factor subject that is rich in TITR cells.
    when JTX-1811 binds to CCR8, it can target the removal of TITR cells through enhanced antibody-dependent cytotoxic mechanisms.
    antibody will submit an IND application in the first half of 2021.
    Jounce will be responsible for the early development of the JTX-1811 until IND approval is obtained, after which Gilead will have an exclusive interest in the development of the JTX-1811.
    . William A. Lee, Executive Vice President of Scientific Research and Development at Gilead, said JTX-1811 is a complement to Gilead's other cancer candidates and has the potential to be a new therapy for 'first-in-class' for patients with solid and hematopathic tumors.
    source: Medical Valley !-- content display ends -- !-- determine whether the login ends.
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.